Quest Diagnostics stock rises 2.58% and outperforms competitors

11 articles · Updated · MarketWatch · Apr 30

Shares closed at $194.20 on Thursday, snapping a two-day losing streak as the S&P 500 gained 1.02% and the Dow rose 1.62%.
Quest beat peers including UnitedHealth and Centene, which both fell, while IQVIA posted a smaller 1.09% gain.
Trading volume reached 1.1 million, above the 50-day average of 926,887, though the stock remained 9.04% below its 52-week high of $213.50.

Quest's stock is called undervalued, but with new debt and rising costs, could its strong growth projections mask significant financial risks?

As AI and at-home testing advance, can Quest's traditional lab model adapt quickly enough to stay ahead of market disruption?